Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice.
Lobeglitazone (Lobe) is a novel thiazolidinedione antidiabetic drug that reduces insulin resistance by activating peroxisome proliferator-activated receptor-gamma (PPARγ). However, the exact mechanisms of antidiabetic effects of Lobe have not been established in an animal model. The aim of this stud...
Main Authors: | Bong-Hoi Choi, Zhen Jin, Chin-Ok Yi, Juhong Oh, Eun Ae Jeong, Jong Youl Lee, Kyung-Ah Park, Kyung Eun Kim, Jung Eun Lee, Hyun-Jin Kim, Jong Ryeal Hahm, Gu Seob Roh |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6034891?pdf=render |
Similar Items
-
Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
by: Sorim Choung, et al.
Published: (2018-01-01) -
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
by: Jaehyun Bae, et al.
Published: (2021-05-01) -
Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
by: Kyoung Min Kim, et al.
Published: (2017-09-01) -
Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice
by: Kyung-Ah Park, et al.
Published: (2020-02-01) -
Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma
by: Na-Rae Shin, et al.
Published: (2018-08-01)